BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
BioCryst to Present at Upcoming Investor Conferences
BioCryst to Report First Quarter 2026 Financial Results on May 6
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
BioCryst Pharmaceuticals (NASDAQ:BCRX) & Polydex Pharmaceuticals (OTCMKTS:POLXF) Head to Head Analysis
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.
Alkeon Capital Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. $BCRX
Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
GSA Capital Partners LLP Acquires 78,827 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst to Present at Upcoming Investor Conference
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Analysts
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) and Prelude Therapeutics (NASDAQ:PRLD)
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
FDA expands approval of BioCryst's rare disease drug for use in young children
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
Fisher Asset Management LLC Lowers Stake in BioCryst Pharmaceuticals, Inc. $BCRX
Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold
BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. Merck KGaA (OTCMKTS:MKKGY) Financial Contrast
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)